Ticker

NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET.

Precipio (NASDAQ: PRPO - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of recent ratings

In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M

Precipio, Inc. (NASDAQ: PRPO - Get Free Report) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 4,048 shares, a growth of 22.5% from the January 15th total of 3,304 shares. Based on an average daily trading volume, of 10,844 shares, the short-interest ratio is presently 0.4

Precipio, Inc. (NASDAQ: PRPO - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $20.29 and traded as low as $19.52. Precipio shares last traded at $19.80, with a volume of 32,703 shares trading hands. Analyst Upgrades and Downgrades A number of